よむ、つかう、まなぶ。
【参考資料6】抗微生物薬適正使用の手引き 第三版 補遺 (40 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/newpage_45318.html |
| 出典情報 | 厚生科学審議会 感染症部会 薬剤耐性（AMR）に関する小委員会 抗微生物薬適正使用（AMS）等に関する作業部会（第6回 11／19）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
125. Liu J, Shu Y, Zhu F. et al. Comparative efficacy and safety of combination therapy with highdose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and
extensively drug-resistant Acinetobacter baumannii infections: A systematic review and
network meta-analysis. J Glob Antimicrob Resist. 2021 Mar;24:136-147.
126. Sadyrbaeva-Dolgova S, Garcia-Fumero R, Exposito-Ruiz M, Pasquau-Liano J, JimenezMorales A, Hidalgo-Tenorio C. Incidence of nephrotoxicity associated with intravenous
colistimethate sodium administration for the treatment of multidrug-resistant gram-negative
bacterial infections. Sci Rep. 2022 Sep;12(1):15261.
127. Durante-Mangoni E, Signoriello G, Andini R. et al. Colistin and rifampicin compared with
colistin alone for the treatment of serious infections due to extensively drug-resistant
Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013
Aug;57(3):349-358.
128. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus
colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant
Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019
Jun;17:66-71.
129. Aydemir H, Akduman D, Piskin N. et al. Colistin vs. the combination of colistin and rifampicin
for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated
pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214-1222.
130. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for
treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents
Chemother. 2014 Sep;58(9):5598-5601.
131. Makris D, Petinaki E, Tsolaki V. et al. Colistin versus Colistin Combined with AmpicillinSulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia
Treatment: An Open-label Prospective Study. Indian J Crit Care Med. 2018 Feb;22(2):67-77.
132. Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in
patients with cancer. Clin Infect Dis. 2014 Nov;59 Suppl 5:S335-9.
133. Falcone M, Tiseo G, Nicastro M. et al. Cefiderocol as Rescue Therapy for Acinetobacter
baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit
Patients. Clin Infect Dis. 2021 Jun;72(11):2021-2024.
134. Falcone M, Tiseo G, Leonildi A. et al. Cefiderocol- Compared to Colistin-Based Regimens for
the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter
baumannii. Antimicrob Agents Chemother. 2022 May;66(5):e0214221.
135. McCreary EK, Heil EL, Tamma PD. New Perspectives on Antimicrobial Agents: Cefiderocol.
Antimicrob Agents Chemother. 2021 Jul;65(8):e0217120.
136. Alosaimy S, Morrisette T, Lagnf AM. et al. Clinical Outcomes of Eravacycline in Patients
Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol
Spectr. 2022 Oct;10(5):e0047922.
137. Isler B, Doi Y, Bonomo RA, Paterson DL. New Treatment Options against CarbapenemResistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2018
Dec;63(1):e01110-18.
138. Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin
Infect Dis. 2019 Nov;69(Suppl 7):S565-S575.
40
extensively drug-resistant Acinetobacter baumannii infections: A systematic review and
network meta-analysis. J Glob Antimicrob Resist. 2021 Mar;24:136-147.
126. Sadyrbaeva-Dolgova S, Garcia-Fumero R, Exposito-Ruiz M, Pasquau-Liano J, JimenezMorales A, Hidalgo-Tenorio C. Incidence of nephrotoxicity associated with intravenous
colistimethate sodium administration for the treatment of multidrug-resistant gram-negative
bacterial infections. Sci Rep. 2022 Sep;12(1):15261.
127. Durante-Mangoni E, Signoriello G, Andini R. et al. Colistin and rifampicin compared with
colistin alone for the treatment of serious infections due to extensively drug-resistant
Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013
Aug;57(3):349-358.
128. Park HJ, Cho JH, Kim HJ, Han SH, Jeong SH, Byun MK. Colistin monotherapy versus
colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant
Acinetobacter baumannii: A randomised controlled trial. J Glob Antimicrob Resist. 2019
Jun;17:66-71.
129. Aydemir H, Akduman D, Piskin N. et al. Colistin vs. the combination of colistin and rifampicin
for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated
pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214-1222.
130. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for
treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents
Chemother. 2014 Sep;58(9):5598-5601.
131. Makris D, Petinaki E, Tsolaki V. et al. Colistin versus Colistin Combined with AmpicillinSulbactam for Multiresistant Acinetobacter baumannii Ventilator-associated Pneumonia
Treatment: An Open-label Prospective Study. Indian J Crit Care Med. 2018 Feb;22(2):67-77.
132. Perez F, Adachi J, Bonomo RA. Antibiotic-resistant gram-negative bacterial infections in
patients with cancer. Clin Infect Dis. 2014 Nov;59 Suppl 5:S335-9.
133. Falcone M, Tiseo G, Nicastro M. et al. Cefiderocol as Rescue Therapy for Acinetobacter
baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit
Patients. Clin Infect Dis. 2021 Jun;72(11):2021-2024.
134. Falcone M, Tiseo G, Leonildi A. et al. Cefiderocol- Compared to Colistin-Based Regimens for
the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter
baumannii. Antimicrob Agents Chemother. 2022 May;66(5):e0214221.
135. McCreary EK, Heil EL, Tamma PD. New Perspectives on Antimicrobial Agents: Cefiderocol.
Antimicrob Agents Chemother. 2021 Jul;65(8):e0217120.
136. Alosaimy S, Morrisette T, Lagnf AM. et al. Clinical Outcomes of Eravacycline in Patients
Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii. Microbiol
Spectr. 2022 Oct;10(5):e0047922.
137. Isler B, Doi Y, Bonomo RA, Paterson DL. New Treatment Options against CarbapenemResistant Acinetobacter baumannii Infections. Antimicrob Agents Chemother. 2018
Dec;63(1):e01110-18.
138. Doi Y. Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clin
Infect Dis. 2019 Nov;69(Suppl 7):S565-S575.
40